Compare PLSE & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLSE | FSK |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.0B |
| IPO Year | 2015 | 2008 |
| Metric | PLSE | FSK |
|---|---|---|
| Price | $52.32 | $11.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 11 |
| Target Price | ★ $67.67 | $12.13 |
| AVG Volume (30 Days) | 362.6K | ★ 2.3M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 3.75% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $480.71 | N/A |
| Revenue Next Year | $177.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $9.72 |
| 52 Week High | $58.94 | $16.31 |
| Indicator | PLSE | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 59.32 |
| Support Level | $49.66 | $10.10 |
| Resistance Level | $56.54 | $11.73 |
| Average True Range (ATR) | 4.03 | 0.35 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 24.10 | 57.21 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.